(Q38843950)

6 September 2017

1 reference

title

Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies (English)

1 reference

6 September 2017

0 references

Hamid Reza Amanatkar

1

1 reference

6 September 2017

Bill Papagiannopoulos

series ordinal

2

1 reference

6 September 2017

George Thomas Grossberg

series ordinal

3

1 reference

6 September 2017

25 May 2016

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

6 September 2017

1 reference

6 September 2017

17

1 reference

6 September 2017

1

1 reference

6 September 2017

7-16

1 reference

Forecasting the global burden of Alzheimer’s disease

6 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Clinical trials of intravenous immunoglobulin for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

The role of amyloid-beta in the regulation of memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14737175.2016.1194203

10.1080/14737175.2016.1194203

21 January 2018

Identifiers

DOI

1 reference

release_zbcelyxgbjh5ve7dlsvizgpwlm

6 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zbcelyxgbjh5ve7dlsvizgpwlm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference